ABOUT
MYELOID
At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies and unleash the power of myeloid cells in cancer.
​
Our proprietary ATAKâ„¢ platform is designed to designed to turn myeloid cells against tumors . These engineered cells find, recognize and penetrate tumors. These cells also prime other elements of the immune system, including T cells, thereby reinforcing the anti-tumor immune response, culminating in cancer eradication.

THE
Myeloid is powered by the discoveries of our founders – a group of world-leading scientists whose expertise spans oncology, immunology, mRNA biology, cell therapy, synthetic biology, and gene delivery.
We’re building a team of talented, driven scientists and other biotech industry experts to turn these discoveries into novel, life-saving treatments for people navigating life with cancer.
TEAM
LEADERSHIP
FOUNDERS
SCIENTIFIC ADVISORY BOARD
Prof. Alberto Montavani, MD – Tumor Macrophage Discoverer
He has received several national and international awards for his research activity, such as the Triennial OECI Award from the Organization of the European Cancer Institutes, the Robert Koch Award for his contribution to tumor immunology and immunotherapy, the American-Italian Cancer Foundation (AICF) Prize for Excellence in Medicine and, most recently, the American Association for Cancer Research International Pezcoller Award for Extraordinary Achievement in Cancer Research. The broad impact of his contributions is evidenced by citations.
As of February 2020 he has over 121,000 citations and an H-index of 167 (Scopus).
Prof. Miriam Merad, MD, PhD – Macrophage & TME Immunologist
Miriam Merad, MD, PhD is a Professor of Oncological Science, Medicine (Hem/Onc division) and Immunology and a member of the Immunology Institute and The Tisch Cancer Institute at the Mount Sinai School of Medicine in New York. Dr. Merad obtained her MD at the University of Algiers, Algeria. She did her residency in Hematology and Oncology in Paris, France and obtained her PhD in Immunology in collaboration between Stanford University and University of Paris VII. She was recruited to Mount Sinai in 2004 and was promoted to the rank of Associate Professor with Tenure in 2007 and to Full Professor in 2010 and obtained an Endowed Chair in Cancer Immunology in 2014.
In 2010 Dr. Merad became the program leader of the Cancer Immunology Immunotherapy group at The Tisch Cancer Institute and the director of the Human Immunomonitoring Center. Dr. Merad’s laboratory studies the mechanisms that regulate the development and function of the mononuclear phagocyte lineage including dendritic cells and macrophages. Her laboratory has made seminal discoveries in macrophage biology revealing their embryonic origin and their local maintenance in situ. Dr. Merad identified many of the mechanisms that control dendritic cells and macrophage development, homeostasis and function in different tissues including the contribution of mononuclear phagocytes to neuronal function, barrier tissue integrity and tumor response to immunotherapy.
Dr. Merad belongs to several NIH-funded scientific consortia including the mucosal immunology study team and the Immgen Consortia to decipher the transcriptional regulation of the tissue dendritic cell and macrophage lineage. Currently, one of the major goals of her laboratory is to identify the contribution of phagocytes to tumor progression and response to treatment in mice and humans.
Dr. Merad has authored more than 150 primary papers and reviews in high profile journals and has obtained extensive NIH funding for her studies on innate immunity in mice and humans.
Prof. Siamon Gordon, MD, PhD – Discovery of Scavenger Receptor
Prof. Nick King, MD, PhD – Virus & Myeloid Cell Expert
Prof. Michael Dee Gunn, MD – T cell Vaccine Biologist
Prof. Michael Lin, PhD – Assoc. Prof. Stanford University
Clinical Cell
Therapy Advisors
Prof. Alberto Montavani, MD – Tumor Macrophage Discoverer
He has received several national and international awards for his research activity, such as the Triennial OECI Award from the Organization of the European Cancer Institutes, the Robert Koch Award for his contribution to tumor immunology and immunotherapy, the American-Italian Cancer Foundation (AICF) Prize for Excellence in Medicine and, most recently, the American Association for Cancer Research International Pezcoller Award for Extraordinary Achievement in Cancer Research. The broad impact of his contributions is evidenced by citations.
As of February 2020 he has over 121,000 citations and an H-index of 167 (Scopus).
Prof. Miriam Merad, MD, PhD – Macrophage & TME Immunologist
Miriam Merad, MD, PhD is a Professor of Oncological Science, Medicine (Hem/Onc division) and Immunology and a member of the Immunology Institute and The Tisch Cancer Institute at the Mount Sinai School of Medicine in New York. Dr. Merad obtained her MD at the University of Algiers, Algeria. She did her residency in Hematology and Oncology in Paris, France and obtained her PhD in Immunology in collaboration between Stanford University and University of Paris VII. She was recruited to Mount Sinai in 2004 and was promoted to the rank of Associate Professor with Tenure in 2007 and to Full Professor in 2010 and obtained an Endowed Chair in Cancer Immunology in 2014.
In 2010 Dr. Merad became the program leader of the Cancer Immunology Immunotherapy group at The Tisch Cancer Institute and the director of the Human Immunomonitoring Center. Dr. Merad’s laboratory studies the mechanisms that regulate the development and function of the mononuclear phagocyte lineage including dendritic cells and macrophages. Her laboratory has made seminal discoveries in macrophage biology revealing their embryonic origin and their local maintenance in situ. Dr. Merad identified many of the mechanisms that control dendritic cells and macrophage development, homeostasis and function in different tissues including the contribution of mononuclear phagocytes to neuronal function, barrier tissue integrity and tumor response to immunotherapy.
Dr. Merad belongs to several NIH-funded scientific consortia including the mucosal immunology study team and the Immgen Consortia to decipher the transcriptional regulation of the tissue dendritic cell and macrophage lineage. Currently, one of the major goals of her laboratory is to identify the contribution of phagocytes to tumor progression and response to treatment in mice and humans.
Dr. Merad has authored more than 150 primary papers and reviews in high profile journals and has obtained extensive NIH funding for her studies on innate immunity in mice and humans.
Prof. Siamon Gordon, MD, PhD – Discovery of Scavenger Receptor
Prof. Nick King, MD, PhD – Virus & Myeloid Cell Expert
Prof. Michael Dee Gunn, MD – T cell Vaccine Biologist
Prof. Michael Lin, PhD – Assoc. Prof. Stanford University
Immunology, Virology & Myeloid Cell Advisors